The introduction of targeted therapy has changed the landscape of metastatic renal cell carcinoma (mRCC) but has also brought challenges.
One such challenge of treating this chronic disease is long-term therapy, which produces ongoing toxicity. Knowledge of the spectrum of toxicity from targeted therapy and appropriate and timely intervention is required to maintain adequate dosing required for optimal outcome. This article addresses some of the major toxicities of newer agents in RCC and discusses management strategies.
Written by:
Kollmannsberger C, Mitchell T. Are you the author?
Division of Medical Oncology, British Columbia Cancer Agency Vancouver Cancer Centre, Vancouver BC V5Z 4E6, Canada.
Reference: Semin Oncol. 2013 Aug;40(4):499-510.
doi: 10.1053/j.seminoncol.2013.05.011
PubMed Abstract
PMID: 23972714
UroToday.com Renal Cancer Section
